Anthem Bioscienc
Anthem Bioscienc Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #62 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Anthem Biosciences aims to maintain a revenue growth rate of around 20%, consistent with its historical performance over the past decade. Anthem Biosciences aims to maintain historical revenue growth of around 20% annually over the medium to long term.
From Anthem Bioscienc's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Anthem Biosciences aims to maintain a revenue growth rate of around 20%, consistent with its historical performance over the past decade.
- The company aspires to continue delivering around 20% growth in EBITDA and PAT alongside revenue growth.
- Recent revenue growth was about 15% due to market adjustments, but EBITDA and PAT grew over 30%.
- The launch of four new commercial molecules contributes around 8-9% to current revenues, with ramp-up expected over 2-3 years.
- Capacity expansions, especially Unit 4 (doubling custom synthesis and increasing fermentation capacity by 50%), position the company for future growth.
- The company anticipates broadening relationships with big pharma, expecting growth through new programs and acquisitions of biotech firms.
2 more points from Anthem Bioscienc's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anthem Bioscienc said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Major ongoing capex is for Unit 4, Anthem's largest project, spanning 30 acres.
- Phase 1 investment of approx. Rs. 1,200 crores over FY27 and FY28, aiming for completion by March 2028.
- Phase 1 will nearly double custom synthesis capacity (adding 365 kiloliters) and increase fermentation capacity by 50% (adding 100 kiloliters).
- Unit 2 and Unit 3 expansions are ongoing (currently in CWIP).
- Post Phase 1, two more phases planned for Unit 4 to further double or triple overall capacity.
- FY27 capex expected around Rs. 700 crores; subsequent year around Rs. 500 crores.
2 more points from Anthem Bioscienc's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anthem Bioscienc said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Specialty Ingredients segment operates as a flow business without a traditional order book; products are manufactured and sold continuously to multiple customers across regions.
- For the CDMO business, order books exist primarily with commercial molecule customers who provide significant lead times, typically up to six months.
- The company has around 100 projects in early stages (discovery, development, optimization), with capacity to handle up to 200 projects without constraints.
- Expansion via Unit 3 and upcoming Unit 4 will increase capacity, supporting future order inflow.
2 more points from Anthem Bioscienc's call on order book
Create a free account to keep reading this call
Anthem Bioscienc — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹611 Cr, net profit ₹190 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anthem Biosciences Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anthem Bioscienc and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anthem Bioscienc Q4 FY26 results?
Anthem Biosciences aims to maintain a revenue growth rate of around 20%, consistent with its historical performance over the past decade. Anthem Biosciences aims to maintain historical revenue growth of around 20% annually over the medium to long term.
What is Anthem Bioscienc share price analysis?
Anthem Bioscienc currently shows a neutral. The stock trades at a P/E of 84.5 with a market cap of ₹50,132 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anthem Bioscienc planning capital expenditure?
Major ongoing capex is for Unit 4, Anthem's largest project, spanning 30 acres. - Phase 1 investment of approx.
Keep Anthem Bioscienc on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.